Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07189897 · ClinicalTrials.gov registry record · Phase 4

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

A Phase 4 study of Head and Neck Cancer and Venous Thromboembolism, sponsored by Kiranya Arnold.

Recruiting
Registry status
Phase 4
Development phase
76
Enrollment target
1
Study location

NCT07189897 is a Phase 4 study of Head and Neck Cancer and Venous Thromboembolism that is actively recruiting participants, run by Kiranya Arnold. The registered enrollment target is 76 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07189897, a Phase 4 study of Head and Neck Cancer and Venous Thromboembolism, is actively recruiting participants, sponsored by Kiranya Arnold.

RECRUITING
Registry status
Phase 4
Development phase
76 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery. It will also learn about side effects of both medicines. The main questions it aims to answer are: Can apixaban be used safely instead of enoxaparin to prevent blood clots after surgery? Do patients find apixaban easier or more satisfying to take than enoxaparin? How well do patients follow the treatment plan with each medicine? Researchers will compare 2 groups: One group will take apixaban (a pill taken twice a day) for 10 days after surgery. The other group will take enoxaparin (a shot given once a day) for 10 days after surgery. Participants will: Take either apixaban or enoxaparin starting 12-24 hours after surgery, for 10 days total Keep a medication diary and bring back unused medicine so the study team can check adherence Complete short surveys about satisfaction with their medicine Have an ultrasound of their legs to check for blood clots 11-14 days after surgery Return for follow-up visits about 40 days and 80 days after surgery for safety checks How long will participation last? About 4 months from surgery through the last follow-up visit.

Conditions Studied

Head and Neck Cancer Venous Thromboembolism

Interventions

  • DRUG Apixaban
  • DRUG Enoxaparin

Study Locations (1)

New York

  • SUNY Upstate - Syracuse

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2025-10
Est. Completion 2027-12
Phase Phase 4

Sponsor

Kiranya Arnold

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07189897

The ClinicalTrials.gov registry entry for NCT07189897 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Kiranya Arnold, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Apixaban is the first listed.

NCT07189897 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT07189897 about?

NCT07189897 is a clinical study titled "Apixaban or Enoxaparin After Head and Neck Cancer Surgery". The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery. It will also learn about side effects of both medicines. The main questions it aims to answer are: Can ap...

What is the current status of trial NCT07189897?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2025-10. Estimated completion is 2027-12.

What conditions does trial NCT07189897 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Venous Thromboembolism.

What interventions are being tested in trial NCT07189897?

The interventions under investigation include: Apixaban (DRUG), Enoxaparin (DRUG).

Who is sponsoring clinical trial NCT07189897?

This trial is sponsored by Kiranya Arnold, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07189897 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Venous Thromboembolism

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.